The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
The regulators in charge of Medicare recently dealt Eli Lilly a setback when they adamantly refused to reimburse for the Alzheimer's imaging agent Amyvid in all but a handful of cases.
NIH is looping Emory's Rollins School of Public Health into its Parkinson's Disease Biomarker Program, pledging $900,000 to a research team aiming to discover new ways of identifying the ailment.
A group of investigators at the NIH say that they've found a neuroimaging biomarker at the back of the brain that could prove effective in personalizing drugs in the future--raising the odds of matching a patient with the best therapy.
A combination of biomarkers and imaging could tag chemotherapy-induced heart damage early on, cutting long-term heart risk in cancer survivors, according to a study reported at the recent San Antonio Breast Cancer Symposium.
Three months after GE Healthcare announced upbeat results from its Phase III study of flutemetamol, which it hopes will become the state-of-the-art imaging agent for Alzheimer's disease, the company announced a key tie-up with Merck.
The latest Parkinson's disease biomarker discovery is the suggestion that eye (ocular) tremor could be used for early diagnosis.
Imaging biomarkers are coming into play; researchers and physicians are looking at physical changes in the structures of organs or tissues to track disease and suggest prognosis.
Losing cognitive abilities is one of the most distressing symptoms of neurodegenerative disorders such as multiple sclerosis. Researchers from the NYU Langone Medical Center, publishing in the